SOURCE: Market Pulse

September 06, 2005 08:45 ET

Market Pulse Breaking News Alert for Tuesday, Sept. 6, 2005: DNAG -- DNAPrint Genomics' Biofrontera AG Business Partner Completes 20 Million Euro Bond Placement!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA -- (MARKET WIRE) -- September 6, 2005 -- Market Pulse News Alert for this AM, Stocks to Watch are: DNAPrint genomics, Inc. (OTC BB: DNAG), Steicher Mobile Fueling Inc. (NASDAQ: FUEL), Albertsons Inc. (NYSE: ABS) and Finisar Corp. (NASDAQ: FNSR).

Investors need to be watching DNAPrint genomics, Inc. (OTC BB: DNAG) this AM! DNAPrint is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology, and consumer genetic tests. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness™, RETINOME™ (a predictive test for inferring eye color from a DNA sample), ANCESTRYbyDNA™, and EURO-DNA™. DNAPrint's management sees exciting growth opportunity in these markets to introduce and sell their novel products and services. DNAG just had excellent news out in a press release before Tuesday's opening bell announcing that Biofrontera has completed a 20 million euro bond placement! This could be great news for investors!

DNAPrint genomics, Inc. (OTC BB: DNAG), which holds an 18% stake in German pharmaceutical company Biofrontera AG, today announced that Biofrontera has completed a 20 million euro bond placement.

The bonds began trading on the Frankfurt exchange on Wednesday under the symbol (ISIN DE 000 A0E 964 9). If Biofrontera completes a public offering in the future, each purchaser in the offering at 100 euros can convert to 6.2 shares of Biofrontera stock. This conversion rate attributes a price of 16.13 euros per share to the Biofrontera common shares. If this accurately represents the fair market value of the Biofrontera common stock, then DNAPrint's 455,179 shares of Biofrontera stock, which it acquired for 1.5 million euros in July 2005, would now be valued at approximately 7.3 million euros.

"We believe our investment in Biofrontera will prove to be beneficial to DNAPrint genomics and to our shareholders," said DNAPrint genomics President and Chief Executive Officer Richard Gabriel. "It validates our decision to build a collaborative relationship with Biofrontera in advance of its anticipated initial public offering."

"Biofrontera is an excellent business partner for us because of its drug-product pipeline," said Hector J. Gomez, Ph.D., Chairman and Chief Medical Officer at DNAPrint genomics. "We are pleased with our relationship with Biofrontera, and we have the highest confidence in its management team. We are confident the new funding will assist Biofrontera in advancing its drugs into the market."

Mr. Gabriel and Dr. Gomez both are members of Biofrontera's Board of Directors.

"DNAPrint genomics, Inc. and its support were crucial to our securing this new financing," said Prof. Hermann Lübbert, Chief Executive Officer of Biofrontera AG. "We look forward to building our relationship with DNAPrint and believe that the synergy of the two companies and their technologies may offer a faster, cheaper and more effective way to develop drugs," he concluded.

Biofrontera already is in Phase II clinical trials for its lead product, an anti-itch compound for chronic Urticaria, or chronic itching. It also has a Phase II clinical trial compound for pre-cancerous skin lesions. In addition, Biofrontera has advanced several compounds to pre-clinical development, including a novel prophylactic migraine treatment.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness™ RETINOME ™ (a predictive test for inferring eye color from a DNA sample), ANCESTRYbyDNA™, and EURO-DNA™. Recently announced and as a part of the Company's Trace Genetics acquisition, DNAWitness-Y and DNAWitness-Mito are two new tests that can be used as identification tools when other DNA testing either fails to yield results or the sample might be too deteriorated.

About Biofrontera AG

Biofrontera is aiming to become a specialty pharma business in dermatology and inflammatory diseases. The company is located in Leverkusen, Germany. Biofrontera's existing investor group includes Heidelberg Innovation, TechnoMedia Kapitalbeteiligungsgesellschaft Köln mbH, and Prof. Dr. Riesner, founder of Quiagen AG. The financial resources provided by the bond will be applied to the further development of Biofrontera's clinical products. The bond will be placed on the Frankfurt Exchange under the symbol (ISIN DE 000 A0E 964 9).

Stocks in the news and acting well as of late include: Steicher Mobile Fueling Inc. (NASDAQ: FUEL), Albertsons Inc. (NYSE: ABS) and Finisar Corp. (NASDAQ: FNSR).

Information contained herein is the opinion of Market-Pulse.com ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company. You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated seventy five thousand dollars from DNAPrint genomics, Inc. MP was also compensated two million restricted shares of common stock directly from DNAPrint genomics, Inc. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. Market-Pulse.com and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information